Gilead's Kite to Acquire Interius BioTherapeutics for $350M, Enhancing In Vivo Platform

Kite, a Gilead subsidiary, is acquiring Interius BioTherapeutics for $350 million in cash to enhance its cell therapy expertise with Interius's in vivo CAR T-cell platform. The acquisition is expected to impact Gilead's 2025 earnings by $0.23-$0.25 per share. Interius's platform has the potential to transform cancer treatment by allowing direct generation of CAR T-cells within patients' bodies, reducing the need for preconditioning chemotherapy or complex cell processing.

Gilead Sciences, Inc. has announced a significant acquisition to bolster its cell therapy portfolio. The company has agreed to acquire Interius BioTherapeutics for $350 million in cash. This strategic move aims to integrate Interius' innovative in vivo CAR T-cell platform into Kite, Gilead's cell therapy subsidiary. The acquisition is expected to impact Gilead's 2025 earnings by $0.23-$0.25 per share [3].

Interius BioTherapeutics specializes in developing next-generation cell therapies using a proprietary platform designed to deliver genetic material directly into cells within the body. This approach contrasts with traditional methods that require removing cells from the patient for modification before reinfusion. By integrating Interius' platform, Kite seeks to enhance its ability to develop more efficient and scalable treatment solutions [2].

The acquisition reflects Gilead's commitment to advancing therapeutic options for patients with unmet medical needs. Interius' technology has the potential to transform cancer treatment by allowing direct generation of CAR T-cells within patients' bodies, reducing the need for preconditioning chemotherapy or complex cell processing [1]. This innovative approach could make cell therapies more accessible and scalable, potentially broadening access to care for patients with aggressive or advanced diseases.

Under the terms of the acquisition agreement, Kite will acquire all of the outstanding share capital of Interius for a total of $350 million in cash consideration, subject to customary adjustments. The transaction is expected to close subject to customary conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act [3].

Gilead's forward-looking statements indicate that the integration of Interius' technology and expertise could accelerate the development of next-generation in vivo therapies. The acquisition is part of Gilead's broader strategy to become a leader in the rapidly evolving cell therapy market [3].

References:
[1] https://www.fiercebiotech.com/biotech/gileads-kite-sails-vivo-car-t-space-350m-interius-buyout
[2] https://www.geneonline.com/kite-pharma-to-acquire-interius-biotherapeutics-for-350-million-to-advance-in-body-cell-therapy-development/
[3] https://finance.yahoo.com/news/kite-acquire-interius-biotherapeutics-advance-123000111.html